News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
688,512 Results
Type
Article (39839)
Company Profile (285)
Press Release (648388)
Section
Business (204671)
Career Advice (2005)
Deals (35420)
Drug Delivery (86)
Drug Development (80952)
Employer Resources (168)
FDA (16130)
Job Trends (14869)
News (345657)
Policy (32541)
Tag
Academia (2580)
Alliances (49375)
Alzheimer's disease (1228)
Approvals (16060)
Artificial intelligence (128)
Bankruptcy (354)
Best Places to Work (11563)
Biotechnology (205)
Breast cancer (117)
Cancer (1065)
Cardiovascular disease (97)
Career advice (1671)
Cell therapy (231)
Clinical research (64292)
Collaboration (375)
Compensation (193)
COVID-19 (2547)
C-suite (93)
Data (1097)
Diabetes (152)
Diagnostics (6162)
Earnings (84899)
Employer resources (146)
Events (109813)
Executive appointments (297)
FDA (16650)
Funding (341)
Gene therapy (176)
GLP-1 (574)
Government (4347)
Healthcare (18704)
Infectious disease (2630)
Inflammatory bowel disease (106)
Interviews (311)
IPO (16309)
Job creations (3660)
Job search strategy (1429)
Layoffs (416)
Legal (7871)
Lung cancer (168)
Manufacturing (175)
Medical device (13211)
Medtech (13216)
Mergers & acquisitions (19173)
Metabolic disorders (397)
Neuroscience (1496)
NextGen Class of 2024 (6520)
Non-profit (4493)
Northern California (1460)
Obesity (227)
Opinion (179)
Patents (101)
People (56551)
Phase I (19990)
Phase II (28310)
Phase III (21103)
Pipeline (452)
Postmarket research (2558)
Preclinical (8513)
Radiopharmaceuticals (235)
Rare diseases (216)
Real estate (5950)
Regulatory (21574)
Research institute (2349)
Resumes & cover letters (351)
Southern California (1284)
Startups (3585)
United States (13274)
Vaccines (550)
Weight loss (166)
Date
Today (176)
Last 7 days (929)
Last 30 days (3713)
Last 365 days (35629)
2024 (32467)
2023 (40145)
2022 (51251)
2021 (55824)
2020 (54228)
2019 (46704)
2018 (35182)
2017 (32290)
2016 (31688)
2015 (37802)
2014 (31495)
2013 (26569)
2012 (28767)
2011 (29449)
2010 (27569)
Location
Africa (718)
Arizona (191)
Asia (37352)
Australia (6093)
California (3273)
Canada (1271)
China (243)
Colorado (143)
Connecticut (146)
Europe (80017)
Florida (446)
Georgia (116)
Illinois (338)
Indiana (194)
Kansas (96)
Maryland (573)
Massachusetts (2571)
Michigan (153)
Minnesota (269)
New Jersey (943)
New York (938)
North Carolina (696)
Northern California (1460)
Ohio (136)
Pennsylvania (836)
South America (1103)
Southern California (1284)
Texas (449)
Utah (89)
Washington State (355)
688,512 Results for "micron biomedical inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Micron Biomedical Announces The Lancet Publication of Positive Phase 1/2 Data From First Clinical Trial of Needle-Free Vaccines in Children
Micron Biomedical, a life science company developing first-in-class dissolvable microarray-based products that simplify and improve the transport, storage, and administration of drugs and vaccines, today announced the publication of its positive Measles and Rubella (MR) Phase 1/2 trial data in The Lancet Medical Journal.
May 1, 2024
·
5 min read
Business
Micron Biomedical Appoints Global Health Pioneer and Champion of Vaccine Access, Dr. Seth Berkley, as Scientific Advisor to the CEO
Micron Biomedical, a life science company developing first-in-class dissolvable microarray-based products that simplify and improve the transport, storage, and administration of drugs and vaccines, announced the appointment of global public health pioneer, Dr. Seth Berkley, as scientific advisor to the CEO.
February 27, 2024
·
3 min read
Press Releases
Micron Biomedical Expands World-Renowned Advisory Team with Appointment of Medtech Innovation Leader, Sandeep Patel, PhD Ahead of Commercial Manufacturing of Its Needle-Free Technology
September 5, 2024
·
4 min read
BioMidwest
Micron Biomedical Receives $23.6 Million to Accelerate Commercial Manufacturing of Needle-Free Vaccines and to Help Eradicate Measles
Micron Biomedical announced a $23.6 million grant from the Bill & Melinda Gates Foundation that will fund mass production of needle-free vaccines.
November 16, 2023
·
4 min read
Business
Micron Biomedical Appoints Brian Bernick, MD as Chairman of Its Board of Directors
Micron Biomedical, a life science company developing first-in-class dissolvable microarray-based products that simplify and improve the administration, transport and storage of drugs and vaccines, today announced the appointment of drug delivery and healthcare innovation veteran, Brian Bernick, MD, as Chairman of the company’s Board of Directors.
August 9, 2023
·
3 min read
Genetown
Micron Solutions, Inc. Board Announces Proposal for Stock Splits
Micron Solutions, Inc., through its wholly-owned subsidiary, Micron Products, Inc. announced the Board’s approval of a proposal to effect a 1-for-1,000 reverse stock split of the Company’s Common Stock, followed immediately by a 1,000 to 1 forward stock split for the Company’s Common Stock, which Stock Splits will be enacted through the filing of amendments to the Company’s Certificate of Incorporation with the Secretary of State of the State of Delaware.
October 2, 2023
·
8 min read
BioMidwest
Micron Biomedical Extends Series A to $17 Million to Bring Needle-Free Drugs and Vaccines to Market
Micron Biomedical announced it has secured an additional $3 million investment from J2 Ventures, bringing its total Series A funding to $17 million.
May 10, 2023
·
4 min read
Drug Development
Micron Biomedical Announces Positive Measles and Rubella Vaccination Results from First Clinical Trial of Microarray Injection-Free Vaccine Delivery in Children
Micron Biomedical today announced positive Phase 1/2 data from the first-ever clinical trial of microarray technology in children including infants as young as 9 months old.
May 17, 2023
·
4 min read
Micron Biomedical Secures Series A Financing to Commercialize MAP Technology for Self-Administration of Drugs and Vaccines without Needles
Micron Biomedical, Inc. secures a $14 million Series A financing will support the company’s development of commercial manufacturing, currently underway and establishes a strong partnership between Micron and LTS Lohmann.
November 28, 2022
·
3 min read
Business
Impact BioMedical Inc. Announces Pricing of Initial Public Offering
September 16, 2024
·
2 min read
1 of 68,852
Next